Eli Lilly and Incyte have another rival in the rear-view mirror for Olumiant in alopecia areata after Pfizer reported that its ritlecitinib improved scalp hair regrowth in a late-stage trial.

Pfizer has picked up approval in the EU for Litfulo, its JAK inhibitor for severe alopecia areata, extending its challenge to Eli Lilly’s first-to-market Olumiant. The European Commission has ...

LAS VEGAS, NV, UNITED STATES, January 15, 2025 /EINPresswire / -- The Alopecia Areata market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period.